Brian Goff - 21 Jul 2021 Form 4 Insider Report for ALEXION PHARMACEUTICALS, INC.

Reporting relationship: EVP & Chief Commercial Officer
Issuer ticker: N/A
Reported as of: 21 Jul 2021
Net transaction value: -$2,178,045
SEC form: 4
Accepted by SEC: 23 Jul 2021, 16:42:07 UTC
Prior SEC filing: 16 Jul 2021
Next SEC filing: 09 Aug 2022
Source filing: View source filing
Reporting owner signature: /s/ Douglas Barry, Attorney-in-Fact for Brian Goff

Key filing fact

Brian Goff filed Form 4 for ALEXION PHARMACEUTICALS, INC. on 23 Jul 2021.

Key facts

This page summarizes Brian Goff's Form 4 filing for ALEXION PHARMACEUTICALS, INC..
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 23 Jul 2021, 16:42.

Change

Previous filing in this sequence was filed on 16 Jul 2021.
Current net transaction value: -$2,178,045.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ALXN transaction

Common Stock, par value $.0001 per share

Disposed to Issuer

Transaction value: $0
Shares: -150,832
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 21 Jul 2021
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ALXN transaction Derivative

Option to Purchase Common Stock

Disposed to Issuer

Transaction value: $2,178,045
Shares: -21,750
Change %: -100%
Price: $100.14
Shares after: 0
Date: 21 Jul 2021
Ownership: Direct
Underlying class: Common Stock, par value $.0001 per share
Underlying amount: 21,750
Exercise price: $100.14
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Brian Goff is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration").

Footnote F2

Upon the First Effective Time, these options were cancelled and converted into the right to receive the product obtained by multiplying (A) the excess, if any, of the value of the Merger Consideration over the exercise price per share of the Alexion common stock subject to such options immediately prior to the First Effective Time by (B) the number of shares of Alexion common stock subject to such option immediately prior to the First Effective Time by (ii) the value of the Merger Consideration.